ERBB2 and inflammatory breast carcinoma: In the Matsuda et al. study [32], HER2-negative IBC patients were treated with chemotherapy plus panitumumab, and the pCR rate was 28.0% (and 42.0% in the subgroup with triple-negative IBC).